Floatz Rating
B62/100
Confidence
Indicative
Sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06465446CT.gov A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT05833984CT.gov Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Classic Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| imm01 (this asset) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | P3 | B · 62 |
| Dacarbazine | City of Hope Medical Center | P3 | BB |
| Adriamycin | Michael Spinner, MD | P3 | BB |
| Vinblastine | University of Washington | P2 | BB |
| Etoposide | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Tislelizumab | Children's Cancer Group, China | P3 | BB |
| Isocyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Brentuximab Vedotin | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Classic Hodgkin Lymphoma cohort
Other indications for imm01
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Atherosclerotic Cardiovascular Disease | — | P2/3 | B · 57 |
| Myelodysplastic Syndrome | — | P1/2 | CC · 41 |
| Acute Myeloid Leukemia | — | P1/2 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. imm01 in Classic Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/imm01-classic-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →